title: Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: a pilot study.
abstract: OBJECTIVE
  To compare clinical outcome and safety of transcatheter arterial chemoembolization (TACE) + portal vein embolization (PVE) with TACE alone in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT).
  
  
  METHODS
  We retrospectively collected patients of HCC with PVTT treated with TACE (5-FU, oxaliplatin and mitomycin) or TACE + PVE (doxorubicin) between October 2000 and July 2008. Outcomes evaluated include overall survival, response to treatment and side effects.
  
  
  RESULTS
  One hundred and sixteen patients were assessed. The median follow-up of TACE group and TACE + PVE group was 83 and 85 months, respectively. The tumor response rates were respectively 48/64 and 49/52. The 1-, 3- and 5-year overall survival rates for the TACE and TACE + PVE groups were 39/64, 16/64, 0/64 and 42/52, 19/52, 6/52 respectively (P = 0.015, 0.046 and 0.002, respectively). Three factors were shown as the risk factors which affect the survival of patients: treated by TACE + PVE or TACE; type of PVTT; and absence of cirrhosis.
  
  
  CONCLUSIONS
  TACE + PVE may be better than TACE alone to treat primary HCC with PVTT.
authors.affiliation: Department of Chemotherapy Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
authors.forename: Xuefen
authors.initials: X
authors.lastname: Tan
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Xie
authors.affiliation: Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
authors.forename: Jibing
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
authors.forename: Huiyong
authors.initials: H
authors.lastname: Wu
authors.affiliation: Department of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
authors.forename: Yinfa
authors.initials: Y
authors.lastname: Xie
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011169:Portal Vein / Q000473:pathology*; D012189:Retrospective Studies; D016019:Survival Analysis; D013927:Thrombosis / Q000601:surgery*; D016896:Treatment Outcome
keywords: hepatocellular carcinoma (HCC); portal vein embolization (PVE); portal vein tumor thrombus (PVTT); transcatheter arterial chemoembolization (TACE)